Page last updated: 2024-11-12

bismuth subgallate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bismuth subgallate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16682999
SCHEMBL ID7892
MeSH IDM0042662

Synonyms (30)

Synonym
NCGC00166280-01
dermatol (tn)
D01398
99-26-3
bismuth subgallate (jp17/usp)
dermatol puder
1,3,2-benzodioxabismole-5-carboxylic acid, 2,7-dihydroxy-
basic bismuth 3,4,5-trihydroxybenzoate
wismutgallathydroxid
gallic acid bismuth basic salt
2,7-dihydroxy-1,3,2-benzodioxabismole-5-carboxylic acid
bismuth subgallate
cas-99-26-3
dtxsid3046588 ,
tox21_112388
bismuth(iii) gallate basic hydrate
SCHEMBL7892
NCGC00166280-02
bismuth(iii) gallate, basic
2,7-dihydroxybenzo[d][1,3,2]dioxabismole-5-carboxylic acid
AKOS030573444
bismuthsubgallate
E75771
mfcd00044980
DB13909
CS-0013442
bismuth-subgallate
HY-B1560
2,7-dihydroxy-2h-benzo[d]1,3-dioxa-2-bismacyclopentane-5-carboxylic acid
EN300-8687037

Research Excerpts

Overview

Bismuth subgallate (BS) is a hemostatic agent used for soft tissue surgery in otorhinolaryngology and dermatology. It is an insoluble analog of ellagic acid, lost its ability to activate Hageman factor on being exposed to BAC770.

ExcerptReferenceRelevance
"Bismuth subgallate is a salt derived from heavy metal. "( Experimental study on the effects of bismuth subgallate on the inflammatory process and angiogenesis of the oral mucosa.
Ballin, CH; Ballin, CR; Couto, EV; Dassi, CS; Maeda, CA; Miura, LY; Sampaio, CP,
)
1.85
"Bismuth subgallate (BS) is a hemostatic agent used for soft tissue surgery in otorhinolaryngology and dermatology. "( Effect of bismuth subgallate (a hemostatic agent) on bone repair; a histologic, radiographic and histomorphometric study in rats.
Bozzini, CE; Guglielmotti, MB; Puia, SA; Renou, SJ; Rey, EA, 2009
)
2.2
"Bismuth subgallate, which is an insoluble analog of ellagic acid, lost its ability to activate Hageman factor on being exposed to BAC770."( Inhibitory action of amyloid precursor protein against human Hageman factor (factor XII).
Embury, PB; Greenberg, BD; Niwano, H; Ratnoff, OD, 1995
)
1.01
"Bismuth subgallate (BSG) is a heavy metal compound which is effective in lowering the incidence of hemorrhage after adenotonsillectomy and has been demonstrated to activate Factor XII. "( Pulmonary sequelae of intraparenchymal bismuth subgallate.
Abdul-Karim, FW; Arnold, JE; Barcello, M; Cozzi, LM; Dugue, C; Maniglia, AJ; Megerian, CA, 1992
)
2
"Bismuth subgallate is an effective agent in preventing hemorrhage after adenotonsillectomy. "( Activation of Hageman factor (factor XII) by bismuth subgallate, a hemostatic agent.
Maniglia, AJ; Ratnoff, OD; Thorisdottir, H, 1988
)
1.98

Effects

Bismuth subgallate (BS) has been marketed as a way to eliminate the odor associated with flatulence and bowel movements.

ExcerptReferenceRelevance
"Bismuth subgallate has been used in wound and gastrointestinal therapy for over a century. "( Elucidation of the elusive structure and formula of the active pharmaceutical ingredient bismuth subgallate by continuous rotation electron diffraction.
Cheung, O; Inge, AK; Öhrström, L; Takki, S; Wan, W; Wang, Y; Xu, H, 2017
)
2.12
"Bismuth subgallate (BS) has been marketed as a way to eliminate the odor associated with flatulence and bowel movements."( Does Bismuth Subgallate Affect Smell and Stool Character? A Randomized Double-Blinded Placebo-Controlled Trial of Bismuth Subgallate on Loop Duodenal Switch Patients with Complaints of Smelly Stools and Diarrhea.
Cottam, A; Cottam, D; Cottam, S; Medlin, W; Richards, C; Surve, A; Zaveri, H, 2018
)
1.72

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In spite of the high dosage as well as the large interindividual variability in the urinary recovery and the serum concentrations potential "toxic" serum levels of 100 micrograms/l were never reached."( [Effect of meals on resorption of bismuth from an oral bismuth gallate/bismuth nitrate preparation].
Klotz, U; Leonhardt, H, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency22.01630.004023.8416100.0000AID485290; AID489007
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
AR proteinHomo sapiens (human)Potency6.43450.000221.22318,912.5098AID743035; AID743036; AID743040; AID743053; AID743063
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.89920.000229.305416,493.5996AID743069; AID743075; AID743077; AID743079
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.00000.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency33.49150.000723.06741,258.9301AID743085
lamin isoform A-delta10Homo sapiens (human)Potency0.79430.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (24.39)18.7374
1990's14 (34.15)18.2507
2000's8 (19.51)29.6817
2010's8 (19.51)24.3611
2020's1 (2.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.15 (24.57)
Research Supply Index3.93 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index78.69 (26.88)
Search Engine Supply Index2.93 (0.95)

This Compound (38.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (13.64%)5.53%
Reviews2 (4.55%)6.00%
Case Studies7 (15.91%)4.05%
Observational1 (2.27%)0.25%
Other28 (63.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Placebo- and Benchmark-controlled, Double-blind Clinical Trial of Anusol Topical Ointment to Evaluate Symptom Relief in Patients With Haemorrhoids [NCT05157711]Phase 366 participants (Actual)Interventional2021-11-25Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]